Figure 1.
Cytochrome P450 (CYP) 17 inhibitors targeting androgen synthesis and androgen receptors (ARs), currently approved and those in advanced stages of clinical development in castration-sensitive or -resistant prostate cancer. Thick arrows denote stimulation, flat lines denote inhibition, and thin arrows denote synthesis. DHEA, dehydroepiandrosterone; DHT, dihydroxy testosterone.
